PCM
VRTX icon

Polymer Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Polymer Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$745K Buy
1,669
+209
+14% +$97.5K 0.08% 284
2025
Q4 		$662K Sell
1,460
-622
-30% -$268K 0.07% 402
2025
Q3 		$815K Buy
+2,082
New +$870K 0.09% 265
2025
Q2 		– Sell
-739
Closed -$358K – 785
2025
Q1 		$358K Sell
739
-77
-9% -$35.9K 0.09% 314
2024
Q4 		$329K Buy
+816
New +$378K 0.09% 161

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Polymer Capital Management's VRTX Position: Q1 2026 in Review

Polymer Capital Management increased its Vertex Pharmaceuticals (VRTX) stake by 14% in Q1 2026, buying an estimated $97.5K and bringing the position to 1,669 shares worth $745K. The position accounts for 0.08% of the portfolio, ranked #284.

Polymer Capital Management first reported a position in VRTX in Q4 2024 and has held it in 5 quarters since. The position peaked at $815K in Q3 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Polymer Capital Management held 1,669 shares of Vertex Pharmaceuticals worth $745K as of Q1 2026.
  • Polymer Capital Management bought 209 Vertex Pharmaceuticals shares in Q1 2026, an estimated $97.5K.
  • Vertex Pharmaceuticals made up 0.08% of Polymer Capital Management's portfolio in Q1 2026, its #284 holding.
  • Polymer Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 5 quarters since.
  • Polymer Capital Management's Vertex Pharmaceuticals position peaked at $815K in Q3 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Polymer Capital Management's 13F filing for Q1 2026, filed 14 May 2026.